Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
FDF
0
Europe
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Lokelma
2. Sodium Zirconium Cyclosilicate
3. Zs-9 Compound
1. Uzsi 9
2. Zs-9 Compound
3. Uzsi-9
4. Unii-d652zwf066
5. Zs 9
| Molecular Weight | 371.50 g/mol |
|---|---|
| Molecular Formula | H6Na2O9Si3Zr+2 |
| Hydrogen Bond Donor Count | 6 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 0 |
| Exact Mass | 369.816199 g/mol |
| Monoisotopic Mass | 369.816199 g/mol |
| Topological Polar Surface Area | 149 Ų |
| Heavy Atom Count | 15 |
| Formal Charge | 2 |
| Complexity | 131 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 4 |
Ion Exchange Resins
High molecular weight, insoluble polymers which contain functional groups that are capable of undergoing exchange reactions (ION EXCHANGE) with either cations or anions. (See all compounds classified as Ion Exchange Resins.)
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
Details:
Lokelma (sodium zirconium cyclosilicate) is an anti-hyperkalaemia (HK) therapy that provides rapid potassium reduction and sustained potassium control.15 It is indicated for the treatment of Hyperkalaemia (HK) in adults.
Lead Product(s): Sodium Zirconium Cyclosilicate
Therapeutic Area: Nephrology Brand Name: Lokelma
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2023
Lead Product(s) : Sodium Zirconium Cyclosilicate
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Update on CRYSTALIZE Evidence Trials
Details : Lokelma (sodium zirconium cyclosilicate) is an anti-hyperkalaemia (HK) therapy that provides rapid potassium reduction and sustained potassium control.15 It is indicated for the treatment of Hyperkalaemia (HK) in adults.
Brand Name : Lokelma
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 01, 2023
Details:
Lokelma (sodium zirconium cyclosilicate) is an anti-hyperkalaemia (HK) therapy that provides rapid potassium reduction and sustained potassium control.15 It is indicated for the treatment of Hyperkalaemia (HK) in adults.
Lead Product(s): Sodium Zirconium Cyclosilicate
Therapeutic Area: Nephrology Brand Name: Lokelma
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2023
Lead Product(s) : Sodium Zirconium Cyclosilicate
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
ZORA Real-World Evidence Demonstrates that Lokelma Substantially Increases Cardiorenal Patients’...
Details : Lokelma (sodium zirconium cyclosilicate) is an anti-hyperkalaemia (HK) therapy that provides rapid potassium reduction and sustained potassium control.15 It is indicated for the treatment of Hyperkalaemia (HK) in adults.
Brand Name : Lokelma
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 02, 2023
Details:
The designation is based on the potential of LOKELMA to reduce serious adverse CV outcomes in this patient population, addressing a significant unmet medical need.
Lead Product(s): Sodium Zirconium Cyclosilicate
Therapeutic Area: Nephrology Brand Name: Lokelma
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2021
Lead Product(s) : Sodium Zirconium Cyclosilicate
Therapeutic Area : Nephrology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOKELMA® Granted Fast Track Designation in the US to Reduce Cardiovascular Outcomes in Patients o...
Details : The designation is based on the potential of LOKELMA to reduce serious adverse CV outcomes in this patient population, addressing a significant unmet medical need.
Brand Name : Lokelma
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 17, 2021
Details:
The approval by the NMPA was based on data from the Phase IIIb DIALIZE trial. The trial showed sustained potassium control pre-dialysis for more patients receiving Lokelma, compared with placebo.
Lead Product(s): Sodium Zirconium Cyclosilicate
Therapeutic Area: Nephrology Brand Name: Lokelma
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 24, 2020
Lead Product(s) : Sodium Zirconium Cyclosilicate
Therapeutic Area : Nephrology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The approval by the NMPA was based on data from the Phase IIIb DIALIZE trial. The trial showed sustained potassium control pre-dialysis for more patients receiving Lokelma, compared with placebo.
Brand Name : Lokelma
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 24, 2020
Details:
The 20 abstracts being presented, will include data on Lokelma (sodium zirconium cyclosilicate), roxadustat & Farxiga (dapagliflozin) across different stages of CKD and AstraZeneca’s ongoing commitment to exploring treatment options across the full continuum of renal care.
Lead Product(s): Sodium Zirconium Cyclosilicate
Therapeutic Area: Nephrology Brand Name: Lokelma
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2020
Lead Product(s) : Sodium Zirconium Cyclosilicate
Therapeutic Area : Nephrology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The 20 abstracts being presented, will include data on Lokelma (sodium zirconium cyclosilicate), roxadustat & Farxiga (dapagliflozin) across different stages of CKD and AstraZeneca’s ongoing commitment to exploring treatment options across the full con...
Brand Name : Lokelma
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 05, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
Regulatory Info : RX
Registration Country : USA
SODIUM ZIRCONIUM CYCLOSILICATE
Brand Name : LOKELMA
Dosage Form : FOR SUSPENSION;ORAL
Dosage Strength : 5GM/PACKET
Packaging :
Approval Date : 2018-05-18
Application Number : 207078
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
SODIUM ZIRCONIUM CYCLOSILICATE
Brand Name : LOKELMA
Dosage Form : FOR SUSPENSION;ORAL
Dosage Strength : 10GM/PACKET
Packaging :
Approval Date : 2018-05-18
Application Number : 207078
Regulatory Info : RX
Registration Country : USA
Regulatory Info : Prescription
Registration Country : Canada
SODIUM ZIRCONIUM CYCLOSILICATE
Brand Name : LOKELMA
Dosage Form : POWDER FOR SUSPENSION
Dosage Strength : 5G/SACHET
Packaging :
Approval Date :
Application Number : 2490714
Regulatory Info : Prescription
Registration Country : Canada
Regulatory Info : Prescription
Registration Country : Canada
SODIUM ZIRCONIUM CYCLOSILICATE
Brand Name : LOKELMA
Dosage Form : POWDER FOR SUSPENSION
Dosage Strength : 10G/SACHET
Packaging :
Approval Date :
Application Number : 2490722
Regulatory Info : Prescription
Registration Country : Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
RLD : Yes
TE Code :
SODIUM ZIRCONIUM CYCLOSILICATE
Brand Name : LOKELMA
Dosage Form : FOR SUSPENSION;ORAL
Dosage Strength : 5GM/PACKET
Approval Date : 2018-05-18
Application Number : 207078
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : Yes
TE Code :
SODIUM ZIRCONIUM CYCLOSILICATE
Brand Name : LOKELMA
Dosage Form : FOR SUSPENSION;ORAL
Dosage Strength : 10GM/PACKET
Approval Date : 2018-05-18
Application Number : 207078
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
